Onyvax Appoints J. Barrie Ward as Chairman
London, October 14, 2002 – Onyvax Ltd, a leading vaccine
therapy company, today announced the appointment of Dr Barrie
Ward as non-executive Chairman. Dr Ward brings more than 20 years
of experience in the pharmaceutical and biotechnology industries.
Dr Ward is currently CEO of KuDOS Pharmaceuticals Ltd, which
recently completed a $45m private financing. He also holds the
position of Chairman of the Board at US-based Avant Immunotherapeutics.
Dr Ward was previously Chairman and CEO of Virus Research Institute,
Inc of Cambridge, MA, until its merger with T Cell Sciences to
form Avant in 1998. Prior to that, he held divisional responsibility
within Glaxo Research & Development. Dr Ward has a PhD in
microbial biochemistry from the University of Bath.
Dr Ward commented, “I am delighted to join Onyvax at this
exciting time, with Phase II trials of its lead product for prostate
cancer well underway. The Company has established firm foundations
and gained a strong position in regulatory affairs and the development
of biologics through its clinical trials programme. I look forward
to working with its proven management team and Board of Directors.”
Dr Ward replaces Barrie S. Haigh, who held the position of Onyvax
Chairman for five years and is now stepping down to concentrate
on other business activities.
Mr Haigh said, “Onyvax has achieved remarkable progress
since its inception and has earned a leadership position in cancer
immunotherapy and biologics. At this pivotal stage in the Company’s
growth, it is appropriate to bring on board a seasoned and respected
individual with proven achievements in big pharma and biotech
on both sides of the Atlantic. I believe the Company is well
positioned for growth, both through its innovative internal R&D
and external alliances. ”